Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group
Patents for C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
02/2010
02/17/2010CN101648946A Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
02/17/2010CN101648945A Synthesis of important irbesartan intermediate
02/17/2010CN101648944A 病毒聚合酶抑制剂 Viral polymerase inhibitors
02/16/2010US7662969 Efficient aziridination of olefins catalyzed by dirhodium catalysts
02/16/2010US7662966 For example, 5-tert-Butyl-2-{2-[4-(1-methyl-piperidin-4-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions
02/16/2010US7662961 5,5'-{Oxybis[ethane-2,1-diyl(methylimino)]}bis[1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonylpyrazole]; pest control of insects, arachnids and helminths
02/16/2010US7662845 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
02/16/2010US7662836 Indazole having analgesic activity
02/16/2010US7662834 Methods of 1H-indol-3-yl-2-oxoacetamide compounds
02/16/2010US7662830 2-{4-[6-(3-Chloro-4-fluoro-phenyl)-2-morpholin-4-yl-pyrimidin-4-yl]-piperazin-1-yl}-nicotinic acid ethyl ester; 5-Methyl-6-{4-[2-(2-methyl-pyrrolidin-1-yl)-6-phenyl-pyrimidin-4-yl]-piperazin-1-yl}-nicotinic acid; treating conditions related to capsaicin receptor activation; neurophathic pain
02/16/2010US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma
02/16/2010US7662818 e.g. 4-[5-(piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; and multiple sclerosis
02/16/2010US7662817 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever; irritable bowel syndrome
02/16/2010US7662816 Cognition activators; neurodegenerative disorders; Alzheimer's disease
02/16/2010US7662813 Triazole compounds that modulate HSP90 activity
02/16/2010US7662811 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use
02/16/2010US7662804 Selective, tissue-specific TPO receptor agonists; thrombocytopenia resulting from radiation or chemotherapy; drug screening; [(N-substituted-2-oxo-1,2-dihydroindol-3-ylidene)hydrazino]-2-phenols; amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injuries, muscular dystrophy
02/16/2010CA2571627C Substituted aryl-amine derivatives and methods of use
02/16/2010CA2539985C Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
02/16/2010CA2445329C 20-hydroxyeicosatetraenoic acid production inhibitors
02/11/2010WO2010017545A2 Triazole compounds that modulate hsp90 activity
02/11/2010WO2010017408A1 Caspase inhibitors and uses thereof
02/11/2010WO2010017401A1 Bi-1h-benzimidazoles as hepatitis c virus inhibitors
02/11/2010WO2010017240A2 Aurora kinase modulators and methods of use
02/11/2010WO2010017035A2 Inhibitors of iap
02/11/2010WO2010016851A1 Process for selectively producing a pyridobenzoxazine carboxylic acid hemihydrate
02/11/2010WO2010016549A1 Tricyclic compound
02/11/2010WO2010016005A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
02/11/2010WO2010015972A1 Diazepine and diazocane compounds as mc4 agonists
02/11/2010WO2010015653A1 Pyrimidine derivatives as activators of soluble guanylate cyclase
02/11/2010WO2010015623A1 Process for the preparation of endothelin receptor antagonists
02/11/2010WO2010015523A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof
02/11/2010WO2010015522A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof
02/11/2010WO2008142550A9 Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
02/11/2010US20100036117 Pyrimidine compound and pests controlling composition containing the same
02/11/2010US20100036116 Process for the preparation of a macrocycle
02/11/2010US20100035929 Unnatural dispyrin analogues, preparation and uses thereof
02/11/2010US20100035892 Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same
02/11/2010US20100035891 Pharmaceutically Active Compounds
02/11/2010US20100035863 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
02/11/2010US20100035862 Novel aza-cyclic indole-2-carboxamides and methods of use thereof
02/11/2010US20100035354 Process for preparing azacytidine intermediate
02/11/2010US20100034827 Novel hiv reverse transcriptase inhibitors
02/11/2010US20100032658 Novel organic electroluminescent compounds and organic electroluminescent device using the same
02/11/2010CA2733159A1 Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof
02/11/2010CA2733153A1 Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
02/11/2010CA2732101A1 Aurora kinase modulators and methods of use
02/11/2010CA2731897A1 Diazepine and diazocane compounds as mc4 agonists
02/11/2010CA2731368A1 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
02/11/2010CA2730448A1 Inhibitors of iap
02/10/2010EP2150547A2 Polymorphic forms of bosentan
02/10/2010EP2150546A2 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
02/10/2010EP2150539A1 Pyridazinone derivatives
02/10/2010EP2150534A1 Isoquinolinone derivatives as nk3 antagonists
02/10/2010EP2150255A1 Quinoxaline derivatives as p13 kinase inhibitors
02/10/2010EP2150115A1 Cyclopropyl pyrrolidine orexin receptor antagonists
02/10/2010EP2086965B1 Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
02/10/2010CN101646666A Tricyclic compounds
02/10/2010CN100588656C Forcipated diimidazoline palladium compound and its application in Suzuki reaction
02/09/2010US7659408 Especially in which the amide nitrogen is substituted with an adamantyl group, e.g., N-adamantyl-4-chloro-5-(o-fluorophenyl)-1-methyl-3-pyrazolecarboxamide; treating hyperglycemia, diabetes or insulin resistance
02/09/2010US7659298 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting
02/09/2010US7659288 5-aminoalkylpyrazole derivatives as pesticidal agents
02/09/2010US7659280 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
02/09/2010US7659279 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer
02/09/2010US7659276 1-{[1-(2,6-dimethylphenyl)-1H-tetrazol-5-yl]phenylmethyl}-4-(3-phenylallyl)piperazine; G-protein coupled receptor antagonist; antidepressant, anxiolitic agent, obesity
02/09/2010US7659272 N-[phenyl or heteroaryl carbonoyl pyridyl] arylsulfonamides; antiinflammatory, antianaphylactic agents; transplant rejection, gastointestinal, respriatory system and skin disorders
02/09/2010US7659265 5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbothioamide; menopause therapy; contraceptive; anticancer agents
02/09/2010US7659264 CGRP receptor antagonists
02/09/2010CA2451240C Cyclic diamine compound with 6 membered ring groups
02/09/2010CA2407112C Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents
02/04/2010WO2010013222A1 Pyrrole carboxylic acid derivatives as antibacterial agents
02/04/2010WO2010013161A1 Fluorinated heteroaryls
02/04/2010WO2010012747A1 New compounds
02/04/2010WO2010012745A2 Benzimidazoles
02/04/2010WO2010012740A1 5-alkynyl-pyrimidines
02/04/2010WO2010012649A1 Piperazine compounds with herbicidal effect
02/04/2010WO2010012637A1 Process for the preparation of bosentan
02/04/2010WO2010012620A1 Pyrrolidin-3-ylmethyl-amine as orexin antagonists
02/04/2010WO2010012442A2 Insecticidal benzenedicarboxamide derivative
02/04/2010WO2010012399A1 Indolylamides as modulators of the ep<sb>2</sb> receptor
02/04/2010WO2010012397A1 N-(indol-3-ylalkyl)(hetero)arylamide derivatives as modulators of the ep2 receptor
02/04/2010WO2010012396A1 5,6 substituted benzamide derivatives as modulators of the ep<sb>2 </sb>receptor
02/04/2010WO2010012121A1 Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia
02/04/2010WO2009153569A3 Cb1 receptor modulators
02/04/2010WO2009129267A3 Small molecule inhibitors of the pleckstrin homology domain and methods for using same
02/04/2010US20100029954 Reactive 1,3'-crosslinked carbocyanines and their bioconjugates
02/04/2010US20100029950 Novel substituted 1h-dihydropyrazoles, their preparation and use
02/04/2010US20100029939 Preparation of ketone amides
02/04/2010US20100029736 2-substituted proline bis-amide orexin receptor antagonists
02/04/2010US20100029699 Matrix metalloproteinase inhibitors
02/04/2010US20100029686 Hcv protease inhibitors and uses thereof
02/04/2010US20100029664 Pyrrolidin-3-ylmethyl-amine as orexin antagonists
02/04/2010US20100029653 Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders
02/04/2010US20100029646 Prodrugs of diphenyl ox-indol-2-one compounds
02/04/2010US20100029645 Inhibitors of Cytosolic Phospholipase A2
02/04/2010US20100029643 Heterocyclyc sulfonamides having edg-1 antagonistic activity
02/04/2010US20100029626 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers
02/04/2010US20100029621 Hexafluoroisopropanol derivatives
02/04/2010US20100029620 Substituted triazoline, tetrazolone and imidazolone derivatives for use as a medicine
02/04/2010US20100029615 Benzimidazole derivatives
1 ... 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 ... 626